Slide 1: Full Year Financial Results 2012
For personal use only Full Year Financial Results 2012 22 August 2012
Slide 2: Forward looking statements
Forward looking statements CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS For personal use only This presentation, including any comments made during or following the presentation, may contain forward-looking statements that are inherently subject to risks and uncertainties, some of which cann
Slide 3: Financial Results Snapshot
Financial Results Snapshot Issued shares 286m For personal use only Current share price $6.44 Market capitalization $1,841M Results 2012 2011 Total revenue & other income 38.3M 120.9M Operating expenses R&D 36.9M 12.0M Manufacturing 22M 3.4M Management 28.1M 11.8M Other 0.0M 1.5M (Losses) / profit b
Slide 4: Financial Results
Financial Results For personal use only Total revenue and other income 2012 2011 Revenue from continuing operations Commercialization revenue 27.7M 14.6M Interest revenue 10.5M 4.7M Other income Government grants 0.1M - Gain on revaluation of investment to fair value - 86.7M Share of losses of equit
Slide 5: Major Accomplishments
Major Accomplishments For personal use only Key highlights of the 2012 year were: 1. Long term follow-up for 60 patients in Phase 2 trial of congestive heart failure (CHF) identifying a MPC dose which prevented any episodes of heart failure hospitalization or death after 30 months 2. Together with T
Slide 6: Major Accomplishments (continued)
Major Accomplishments (continued) For personal use only 6. Clinical and preclinical development of intravenous product formulation for a wide range of systemic diseases • generated positive preclinical results in primate model of Type 2 diabetes • commenced Phase 2 trial for Type 2 diabetes and its
Slide 7: A risk managed business model
A risk managed business model For personal use only Proprietary platform technology delivers multi-product pipeline – multiple shots on goal – not dependent on success of any one product Corporate partnerships manage execution risk – Teva provides global distribution capability, regulatory and c
Slide 8: Technology
8 For personal use only Technology
Slide 9: Our proprietary adult stem cells
Our proprietary adult stem cells For personal use only potent, purified adult mesenchymal precursor cells – strong safety profile – avoid ethical and safety issues – backed by strong patent position “off the shelf” – classic pharmaceutical drug model – batch to batch consistency – clear, rapid r
Slide 10: Product Pipeline
For personal use only 10 Product Pipeline
Slide 11: Patented Platform Technology Delivers Multi-Product Pipeline
Patented Platform Technology Delivers Multi-Product Pipeline Intravenous products for diabetic and metabolic diseases For personal use only Type 2 early diabetes Kidney/heart/liver complications Intravenous products for inflammatory/immune mediated diseases Inflammatory joint diseases - Rheuma
Slide 12: Lead products pipeline by phase
“Off-the-shelf” products IND clearance FDA approval Lead products Pre-clinical Phase II Phase III Diabetes/Metabolic s Disease Products For personal use only Early Type 2 Diabetes Diabetic Complications (kidney/liver) Immunomodulatory/Inflammatory Products Rheumatoid Arthritis Asthma, Pulmonary Fibr
Slide 13: Congestive heart failure Phase program
Congestive heart failure Phase 3 program For personal use only “In general, Phase 3 studies should use endpoints such as mortality and cardiovascular or heart failure hospitalizations, whereas endpoints, such as ejection fraction, that have not been validated as surrogates for clinical outcome are n
Slide 14: Integrated Metabolic Mechanisms of Action of MPCs
Integrated Metabolic Mechanisms of Action of MPCs For personal use only Pre-Osteoblast Osteoblast Ocn ucOCN Adipo1R, 2R Adiponectin ↑Insulin sensitivity Bone-marrow derived MPCs ↓HGP Adiponectin ↓Lipotoxicity Adipocytes Other potential MPC effects in diabetes: anti-inflammation, Paracrine effects Im
Slide 15: Conclusions From Preclinical Studies In Type 2 Diabetes
Conclusions From Preclinical Studies In Type 2 Diabetes For personal use only • Sustained 6-month durability of glucose lowering effect by single intravenous injection of allogeneic MPC at 0.3, 1 or 2 million MPC/kg; • Accompanying sustained reductions in CRP levels suggest a potential cardioprotect
Slide 16: Rheumatoid Arthritis (RA)
For personal use only Rheumatoid Arthritis (RA) • $10 billion global market, continues to grow • Single agents targeting TNF-alpha or IL-6 moderately effective • Single biologic agents require chronic use, associated with infectious complications • Clear clinical need for novel, single use, remissio
Slide 17: Conclusions From Preclinical Studies Of Inflammatory Arthritis
Conclusions From Preclinical Studies Of Inflammatory Arthritis For personal use only • Collagen-induced arthritis in sheep is good model for human RA • Intravenously-injected allogeneic MPCs selectively migrated to inflamed joints/lymph nodes • Single intravenous MPC injection significantly reduced
Slide 18: Near-Term Value Inflexion Points
Near-Term Value Inflexion Points For personal use only Continued focus on intravenous product franchise – completion of Phase 2 trial in early Type 2 diabetes commencement of Phase 2 trial in diabetic complications commencement of Phase 2 trials in rheumatoid arthritis Completion of Phase 2 spin
Slide 19: Leading the world in novel adult stem cell therapies
For personal use only Leading the world in novel adult stem cell therapies